13 November 2017 - - The global sexually transmitted diseases drug market was valued at USD 32,826.3m in 2016 and is projected to expand at a CAGR of 11.2% from 2017 to 2025 to reach USD 83,041.3m by 2025, according to a report from market intelligence company Transparency Market Research.

The global sexually transmitted diseases drug market can be segmented on the basis of disease type, therapy class, distribution channel, and region.

On the bases of disease type, sexually transmitted diseases drug market can be further segmented into chlamydia, gonorrhea, syphilis, human papillomavirus infection, HIV/AIDS and others.

According to therapy class sexually transmitted diseases drug market can be segmented into antibiotics, antiviral, vaccines and others.

Antibiotic is group of medicines used in the treatment of infections caused by germs-bacteria. It is a most frequently prescribed product in modern medicine.

The first antibiotic was penicillin, discovered by Scottish scientist Alexander Fleming. Today, more than 100 different antibiotics are available in the market to cure minor, and life-threatening infections.

An antiviral is an agent that eliminates a virus or restrains its ability to multiply and hence, prevents it from replicating and reproducing.

 Antiviral drugs are used in the treatment of lethal viral infections caused by viruses like human immunodeficiency virus, hepatitis, influenza A and B viruses and herpes viruses.

Vaccination has been promoted as a vital public health intervention across the globe for decades.

According to the World Health Organization, vaccination has reduced the global burden of infectious disease to a great extent. According to WHO, 36.7m people were living with HIV at the end of 2016.

Geographically, the global sexually transmitted diseases drug market is segmented into five regions: North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 

North America dominated the market and is anticipated to gain more market share from others region by the end of 2025.

The growth of North America is attributed to its well established industry, adoption of new treatment and technologies. Followed by the North America, Europe is the second leading share holder of global sexually transmitted diseases drug market.

Developing economies such as China and Japan are projected to contribute to growth of the market in APAC between 2017 and 2025, due to better health care infrastructure, economic growth, increase in the number of insurance payers, growth of the private health care sector, and increasing education awareness.

The economic growth allows the substantial growth of the middle income group which has enabled the group to access private health care services, and it helps in increasing government spending on the health care sector which provides greater access to health care products and services.

Key players operating in the global sexually transmitted diseases drug market are Pfizer INC, Hoffmann La Roche, Bayer Healthcare, Eli Lilly, Johnson and Johnson, Bristol-Myers Squibb Co. AbbVie, Inc., Gilead Sciences, GlaxoSmithKline Plc, and Merck and Co., Inc.